A clinically applicable mathematical model was developed by researchers to predict outcomes to immunotherapy for patients with cancer previously treated with anti–CTLA-4 or anti–PD-1/PD-L1 antibodies.
Interim data from cohort B of KEYNOTE-555, a phase I trial evaluating a 400 mg every 6-week dosing regimen of pembrolizumab in patients with metastatic melanoma, demonstrated a consistent benefit-risk profile.
The FDA approved an additional recommended dose of 400 mg pembrolizumab (Keytruda) every 6 weeks across all adult indications.
The study found that pembrolizumab has activity in brain metastases from non-small cell lung cancer that is similar to its systemic activity and can result in prolonged survival in a subset of patients.
A recent study determined 4 distinct long noncoding RNA-based immune classes for patients with cancer and provided scores for integration into multiomic panels for precision immunotherapy.
Researchers found that the potential availability of CAR T-cell therapies for large B-cell lymphomas with lower adverse event rates that are suitable for outpatient administration may reduce the total costs of care.
The FDA cleared the investigational new drug (IND) application for the use of CYNK-001 in adults with COVID-19.
Researchers analyzed a patient population with stage IV melanoma and found no difference in the rate of surgical resection with the use of immunotherapy between the checkpoint inhibitor era and pre-checkpoint inhibitor era.
Dylan Essner discussed the implementation of documentation tools and CRS, ICANS and ICE flow sheets within CAR T-cell therapy.
The associate director for clinical research at the Washington University School of Medicine spoke about the value and challenges of using EMRs in CAR T-cell therapy.